An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers

Size: px
Start display at page:

Download "An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers"

Transcription

1 Aerosol Science and Technology ISSN: (Print) (Online) Journal homepage: An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers B. K. Huynh, Y. Chen, D. F. Fletcher, P. Young, B. Zhu & D. Traini To cite this article: B. K. Huynh, Y. Chen, D. F. Fletcher, P. Young, B. Zhu & D. Traini (2015) An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers, Aerosol Science and Technology, 49:10, , DOI: / To link to this article: Accepted author version posted online: 20 Aug Published online: 20 Aug Submit your article to this journal Article views: 499 View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at

2 Aerosol Science and Technology, 49: , 2015 Copyright Ó American Association for Aerosol Research ISSN: print / online DOI: / An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers B. K. Huynh, 1,2 Y. Chen, 2,3 D. F. Fletcher, 4 P. Young, 2,3 B. Zhu, 2,3 and D. Traini 2,3 1 School of Aerospace, Mechanical and Mechatronics Engineering, The University of Sydney, New South Wales, Australia 2 Department of Respiratory Technology, Woolcock Institute of Medical Research, Glebe, New South Wales, Australia 3 Discipline of Pharmacology, Sydney Medical School, University of Sydney, New South Wales, Australia 4 School of Chemical and Biomolecular Engineering, University of Sydney, New South Wales, Australia A methodology for studying the deagglomeration performance and emptying behavior of micronized mannitol powder from two commercial capsule-based dry powder inhalers (DPIs), the lowand high-resistance RS01 Ò, is presented. Mathematical modeling played a key role in the interpretation of the powder release behavior from these two DPI systems. Non-linear regression models, which were characterized from the aerosol obscuration versus time profiles obtained from laser diffraction particle sizing data, were used to estimate rate constants for emptying of mannitol powder. The effects of device resistance and associated pressure drops, sampling flow rate, rates of powder emptying, and the presence of capsule on the dispersion characteristics were studied. The presence of a capsule significantly improved the aerosolization performance of mannitol powder from both inhalers, which may be due to the extended powder air device interactions within the device. It is important to consider the stochastic nature of movement and physical state of the capsule when assessing the aerosolization mechanisms and dispersion performance from these complex delivery systems. The methodology set out in this study has the capacity to provide a greater level of detail in the study of aerosol plume characteristics from capsule-based DPIs. 1. INTRODUCTION Dry powder inhalers (DPIs) for inhalation therapy provide an alternative to the traditional pressurized metered dose inhaler (pmdi) for the treatment of localized lung diseases (Suarez and Hickey 2000). To ensure effective drug delivery into the deep lungs, DPIs rely on patient s inspiratory flow to overcome device resistance and aerosolize powder formulation to form an air/powder dispersion (Cegla 2004). Unlike pmdi, Received 24 April 2015; accepted 6 August 2015 Address correspondence to D. Traini, Respiratory Technology Group, Woolcock Institute of Medical Research, 431 Glebe Point Road, New South Wales 2037, Australia. daniela. traini@sydney.edu.au the design of each DPI is unique. Through careful construction of turbulence generating/particle impaction grids and air pathways, there is potential to improve the dispersion behavior of powder from the entrained airflow (Islam and Cleary 2012). The structural design of DPIs determines the intrinsic resistance to airflow, and have been categorized as low- (LR), medium- (MR), or high-resistance (HR) DPIs (Hindle and Byron 1995). The resistance of device has been reported to have fundamental consequences on aerosolization performance from these delivery systems. For instance, an increase in device resistance due to reduction in the inhaler air inlet dimension causes higher flow velocities that can increase particle impaction forces with the device walls and result in higher flow turbulence levels sufficient to deagglomerate powder formulation (Coates et al. 2006). Therefore, attempts to better understand the powder dispersion behavior and delivery characteristics from complex DPI systems as a function of device resistance have been explored (Hira et al. 2012). While less complex than their pmdi counterparts, DPIs still require a successful combination of components to work well, and can be categorized as either single-unit dose (capsulebased) or multi-unit (blister or reservoir) devices. One factor that has been addressed very little in the published literature on the design aspects of capsule-based DPIs, is the overall capsule interaction with the device and its influence on powder aerosolization and delivery performance. With different commercial inhalers having various designs and capsule chambers, which influence the airflow and consequently control the motion of capsule and degree of powder release, the working principles following powder aerosolization coexisting within single-unit dose DPIs can differ significantly (Behara et al. 2014). For instance, in the Rotahaler Ò DPI (Glaxo- SmithKline, UK), the capsule is split open by a twisting mechanism and the powder is completely released into the airstream. Conversely, with the Dinkihaler Ò DPI (Aventis, 902

3 PARTICLE SIZE DISTRIBUTION AND POWDER RELEASE BEHAVIOR 903 USA), the capsule ends are punctured by a piercing mechanism during actuation and the powder is released from the pierced ends upon inhalation, with the capsule spinning and rattling inside the inhaler (Chew and Chan 1999). A comparative study between these devices demonstrated that variations in generated pressure drops and powder emptying period are due to differences in inhaler design, presence of capsule, and dispersion mechanisms (Chew et al. 2002). Inertial impaction apparatuses, such as the multi-stage liquid impactor and cascade impactors, have been widely used for particle size measurement of the emitted aerosol dose into aerodynamic size classes that are relevant to deposition in the respiratory tract. However, details of the powder release behavior cannot be established from these analytical techniques and therefore the kinetics of powder deagglomeration is poorly understood (de Boer et al. 2002). Real-time laser diffraction analysis, which provides a direct way of capturing the plume duration and powder emptying behavior, can be used to obtain fundamental details of powder deagglomeration and powder release as reported by a number of authors (Kippax and Morton 2008; Behara et al. 2011; Behara et al. 2012). Empirically, it is known that the capsule significantly improves the powder deagglomeration of pharmaceutical aerosols (Chew et al. 2002). However, these observations have never been demonstrated via a quantitative approach. Therefore, the major objective of the present study was to assess the aerosol generation mechanisms of capsule and the effect of device resistance and flow rate on the powder deagglomeration process by adopting a rapid screening method to characterize the release behavior of pharmaceutical powder formulation. The approach used in this study is similar to that described by Behara et al. (2011), however, with attention concentrated on the influence of capsule on powder dispersion behavior. 2. MATERIALS AND METHOD 2.1. Materials Micronized mannitol powder was supplied by Pharmaxis (NSW, Australia), and was employed as the model drug in this study. Mannitol powder was stored in a desiccator over silica gel until use. The inhalers, LR and HR RS01 Ò DPIs (Plastiape S.p.A, Osnago-Lecco, Italy) were used to disperse the powder formulation. Both DPIs are equivalent in shape and size, consisting of two tangential air inlets, with the inlet area of the HR inlet being one-third of the LR inhaler Methodology To assess the influence of capsule on the powder deagglomeration process, mannitol powder was either weighed directly on the base of the inhaler while keeping it in an upright position or preloaded into gelatin capsules (size 3, Capsugel Ò, NSW, Australia) and placed into the device. The DPIs were actuated via a piecing mechanism, using the pins (one at each side) located at the base of the inhaler to produce one hole at each end of the capsule Pressure Drop Flow through both inhalers was produced using a vacuum pump (Westech Scientific Instruments, UK) and recorded using a digital flow meter (Series 4000, TSI Inc., Shoreview,MN,USA)testedoverarangeofairflowrates (30to100Lmin 1 ).Thedeviceresistancewascalculated as the slope of the plot of the square root of the measured pressure drop over the flow rate as reported by Clark and Hollingworth (993). The pressure drop readings across each device were measured with and without capsule to assess the effect of capsule on the resistance of both DPIs Primary Particle Size Analysis The primary particle size distribution of the micronized mannitol powder was determined using a wet dispersion apparatus by means of light scattering (Mastersizer Hydro MV, Malvern Instruments, Worcestershire, UK). Prior to the measurement, approximately 15.0 mg of mannitol powder was sonicated in 15.0 ml of cyclohexane. Sonicating the suspension for a period of 5 min was enough to completely disperse mannitol agglomerates into their primary size ranges. The suspension was immediately transferred to the automated dispersion unit where automated particle sizing was performed. The refractive indices of mannitol and cyclohexane were set to and 1.426, respectively (Zhu et al. 2015). The volume median diameter of mannitol was measured to be mm (n D 3; mean SD) Aerosolization Performance The aerosolization performance of mannitol powder dispersed from the LR and HR inhalers was assessed using laser diffraction for particle size distribution measurements (Spraytec Ò, Malvern Instruments, Worcestershire, UK). Approximately mg of mannitol powder was directly loaded, with and without capsule, and dispersed using both inhalers at 30, 60, and 90 L min 1 for a standard total inhalation volume of 4.0 L. Airflow rates were monitored using the TSI digital flow meter (Series 4000, TSI Inc., Shoreview, MN, USA) and controlled by varying the valve of vacuum pump (Westech Scientific Instruments, UK). The setup was disassembled after each run and cleaned with deionized water to remove any possible mannitol particles that could obscure lenses. Measurements were performed in triplicate to obtain mean values.

4 904 B. K. HUYNH ET AL Powder Release Behavior As mannitol powder passes through the measurement cell at different concentrations in the Spraytec Ò apparatus, the laser detector was able to record changes in laser intensity as a function of time (laser obscuration profile). The measurement was automatically triggered once the laser transmission intensity fell below 99%, capturing data at an acquisition rate of 2.5 khz for each run. The obscuration profiles were modeled in GraphPad Prism 6.0 (GraphPad Software, Inc., CA, USA) using a non-linear least squares approach, details of which are presented in Sections 3.4 and Statistical Analysis Statistical analysis using unpaired two-tailed t-tests was performed in GraphPad Prism 6.0. Significance was determined at 95% confidence interval (CI), with p-values less than 0.05 indicating the values of significance. 3. RESULTS 3.1. Pressure Drop Figure 1 displays the plot of the square root of pressure drop versus flow rate for both LR and HR with and without capsule. The mean inhaler resistance for LR and HR DPIs without capsule was measured and found to be and kpa 1 /2 (L min 1 ) 1, respectively. The corresponding pressure drop values for LR and HR at each tested flow rate, with and without capsule, are summarized in Table 1. These measured values were in general agreement with the values presented in the previous study by Elkins et al. (2014). Such resistances were expected due to the differences in air inlet dimensions, as discussed by Coates et al. (2006). Interestingly, FIG. 1. Relationship between airflow rate and generated pressure drop for low- (LR) and high-resistance (HR) RS01 Ò inhalers, with and without a capsule. Coefficient of correlation values were greater than for all regression lines. TABLE 1 Pressure drop measurements, with and without capsule, for low-resistance (LR) and high-resistance (HR) RS01 Ò inhalers at 30, 60, and 90 L min 1 flow rate Flow rate (L min 1 ) Without capsule (kpa) With capsule (kpa) LR HR LR HR resistances for LR and HR were significantly lower when the capsule was present in the device, recording mean values of and kpa 1 /2 (L min 1 ) 1, respectively. It has been demonstrated by Coates et al. (2005b) that the presence of capsule in Aerolizer Ò DPI, which is similar to RS01 Ò DPI, significantly reduced the overall turbulence levels. This explains significant reduction in resistance to airflow from both HR and LR devices when the capsule was present (p 0.006) Emitted Dose The emitted dose (ED) from both inhalers was determined by subtracting the amount of mannitol remaining in the DPI from the initial mass of mannitol loaded. The influence of pressure drop and the presence of capsule on emitted dose for LR and HR devices are illustrated in Figure 2. In general, an increase in emitted dose was evident in both cases where mannitol was loaded directly into inhaler and capsule, and was more prominent at lower pressure drops. This behavior was expected due to an increase in energy associated with higher pressure drops, as reported by Coates et al. (2005a). When comparing the effect of capsule at each tested flow rate, the emitted dose was found to be generally comparable at most flow rates. When the LR device was operated at 30 L min 1, mannitol powder was found to remain at the base of the device for experiments without capsule, which explains decrease in emitted dose from 73.8% (with capsule, 0.30 kpa) to 58.1% (without capsule, 0.50 kpa). In this scenario, the presence of capsule enabled the entrained air to empty powder from two pierced ends in a more efficient manner. Conversely, the presence of capsule at 60 L min 1 significantly decreased the emitted dose from the HR device from 81.7% (without capsule, 5.50 kpa) to 72.5% (with capsule, 4.10 kpa), respectively. When comparing emitted dose from both devices, HR device was found to perform less efficiently, requiring a higher pressure drop to deliver approximately the same amount of powder from the inhaler.

5 PARTICLE SIZE DISTRIBUTION AND POWDER RELEASE BEHAVIOR 905 TABLE 2 Corresponding volume medium diameter (X 50 ) of aerosolized dose measured from Malvern Spraytec Ò (n D 3; mean SD) without and with capsule Device Flow rate (L min 1 ) Without capsule With capsule LR HR FIG. 2. Emitted dose as a function of pressure drop for low- and highresistance RS01 Ò inhalers (n D 5; mean SD) Aerosolization Performance The aerosolization performance of mannitol powder dispersed with and without capsule from LR and HR inhalers at different flow rates is illustrated in Figure 3. To fully differentiate the extent of powder deagglomeration, the corresponding volume medium diameter (X 50 ) of the emitted dose, with and without capsule, at each tested flow rate is tabulated in Table 2. No significant change in X 50 was observed with increasing flow rates when mannitol powder was dispersed without capsule. As expected, a substantial improvement in the aerosolization performance was evident when mannitol powder was dispersed with capsule, resulting in a shift in the particle size distribution curve to the finer region (Figure 3). It is evident for experiments without a capsule that the device delivers powder of large particle sizes throughout the aerosolization process, particularly at the early stages of powder release. This effect is demonstrated in Figure 4, which compares the change in X 50 as a function of time from LR at 90 L min 1 with and without a capsule. However, by loading mannitol powder into the capsule, large agglomerates are required to first disintegrate into smaller particles and exit the pierced ends of the capsule. It has been reported by Coates et al. (2005a) that the shearing of mannitol agglomerates in FIG. 3. Influence of flow rate and presence of a capsule on the mean cumulative volumetric particle size distributions of aerosolized mannitol powder measured from Malvern Spraytec Ò at (a) 30, (b) 60, and (c) 90 L min 1 (n D 3).

6 906 B. K. HUYNH ET AL. FIG. 4. Typical example illustrating changes in X50 transmission profiles of mannitol powder dispersed with and without capsule from the low-resistance RS01 Ò inhaler at 90 L min 1. FIG. 5. Typical example showing the obscuration profiles of mannitol powder dispersed with and without capsule from low resistance at 90 L min 1. the capsule could have facilitated the deagglomeration mechanism, which could be the case here. Similarly, X 50 transmission profiles were evident for the dispersion of mannitol from both inhalers at all tested flow rates. Generally, a significant reduction in X 50 was evident at increasing flow rates for dispersion with capsule except at 90 L min 1. However, it is important to note that at this flow rate the shattering of capsule occurred, which significantly enlarged the pierced ends, resulting in high variations in measured X 50 values from run to run. It is claimed that the shattering of capsule did not prevent larger powder agglomerates from exiting the capsule, which is reflected by discrete steps in the particle size distribution (Figure 3c). Therefore, it is postulated that the degree of deagglomeration of mannitol powder from LR and HR devices not only depend on the resistance of the device, flow rate, and the presence of capsule but may also be dependent on how the powder is metered from the capsule Powder Emptying Profiles The Spraytec Ò laser diffraction apparatus determines the concentration of the aerosolized sample in the measurement cell by measuring the laser light intensity reduction caused by the aerosolized powder, and is given as a percentage. Therefore, by recording changes in laser obscuration as a function of aerosolization time, the powder emptying behavior of aerosolized mannitol powder from LR and HR inhalers can be obtained, which fundamentally could not be achieved using conventional inertial impaction techniques. Figure 5 shows the obscuration profiles for the dispersion of mannitol powder with and without a capsule from LR at 90 L min 1. The obscuration profiles for LR and HR at all tested flow rates were similar in shape to that shown in Figure 5. Qualitatively, the behavior of powder release shows a rapid rise to a maximum obscuration value (initial powder release), followed by a decaying phase (final powder release). The parameters derived from the obscuration profiles the peak obscuration percentage (%PO), and the time taken to reach peak obscuration, t PO, characterize the rate at which mannitol powder is emptied. The values of these parameters were obtained from each run, and are presented in Table 3. In the case where mannitol powder was dispersed without a capsule, a significant increase in powder release was observed with flow rate as %PO values increased and corresponding t PO values decreased significantly. Presence of a capsule played a crucial role in the emptying behavior of mannitol from both inhalers. First, the dispersion of powder from a capsule significantly decreased the %PO values at all flow rates and increased the time taken to reach peak obscuration in most cases (with the exception of HR operated at 30 and 90 L min 1 ).ItwasreportedbyJiangetal. (2012) that increase in powder residence time inside the inhaler increases the interaction between the dispersed powder, air stream, and device, which could potentially aid in the powder deagglomeration process, as in our experiment. Second, it is important to note significant variability in the powder emptying behavior for the dispersion of mannitol powder with a capsule. This variability was expected as the powder had to be first released from the two ends as the capsule continuously spun and affected the walls of the device. The above findings reveal the highly complex nature of emptying behavior of capsule, the importance of considering the motion and physical state of capsule, and how it influences the powder release behavior and subsequent dispersion performance. Therefore, in order to assess the importance of capsule on powder deagglomeration, modeling of obscuration profiles to attain the rates of empting is undertaken.

7 PARTICLE SIZE DISTRIBUTION AND POWDER RELEASE BEHAVIOR 907 TABLE 3 Powder obscuration data tabulating %PO and t po parameters (n D 3; mean SD) Device Flow rate (L min 1 ) Without capsule With capsule %PO t PO (ms) %PO t PO (ms) LR HR Rates of Emptying Data for the obscuration profiles were fitted using two independent mathematical models. The initial powder release (from the start of transmission to reaching t PO ) displayed a sigmoidal behavior and was modeled using the following Boltzmann sigmoidal modified function: %PO 0 y.t/ D n o [1] 1 C exp [ t t 50 t empty ] where %PO 0 is the peak calculated obscuration value in percentage form, t 50 is the time taken to reach half of %PO 0 in seconds, and t empty describes the slope of the function, with a larger t empty value indicating a slower emptying behavior of inhaler. Fitting of transmission profile to Equation (1) was tested for all triplicates. The final decay phase of the obscuration profile was fitted to a single-decay rate constant according to the following equation: y.t/ D A 0 e k dm t C B 0 ; [2] where A 0 is the difference in obscuration percentage from %PO to baseline reading; B 0 is the baseline; and K dm corresponds to the single-decay rate constant and has units in s 1. Modeling of the final powder release behavior using Equation (2) was performed for all triplicate experiments and was fitted from t PO to the end of the aerosolization period. To evaluate the overall appropriateness of each model to the experimental data, an assessment of parameter dependency was carried out. The concept of dependency describes the degree to which the estimated parameter is dependent upon other parameters within the mathematical model (Knott and Shrager 1972). For instance, if a change in any one parameter of the model results in changes in other parameters such that the overall functional curve remains unchanged or results in minor changes, the parameters are regarded to be highly dependent on one another as reported by Knott and Shrager (1972). The statistical software GraphPad Prism 6.0 quantifies this degree of dependency from 0.0 (parameters are entirely independent) to 1.0 (parameters being entirely dependent), with dependency values greater than 0.99 being undesirable. The correlation coefficient for each estimated parameter is tabulated in Table 4 for both sigmoidal and single-decay rate models. Correlation coefficient (R 2 ) was greater than 95% for most cases. With dependency values being less than 0.99, the proposed models provide acceptable approximations to the experimental data. Thus, the models can be used as a starting point for the analysis of the relationships between pressure drop, powder release behavior, and dispersion performance. Convergence in the fitting of the sigmoidal model could only be obtained for all experiments without a capsule, and in some cases for experiments with a capsule. As such, the t empty parameter could be calculated for most flow rates, but not all (Table 4). A likely explanation is the variable nature of rattling motion of capsule inside the inhaler, as described by Sim et al. (2014). Figure 6 compares the individual initial release behavior of mannitol powder for all triplicate experiments with and without capsule from the LR sampled at 90 L min 1. Greater variations in obscuration profiles at initial phase between each capsule experiment (Figure 6b) were observed as opposed to the experiment without capsule. These results show that the presence of capsule plays an integral role in the mechanisms of powder release and aerosolization due to the chaotic movement of capsule and its impaction onto the walls of inhaler. The influence of pressure drop and the presence of a capsule on the emptying behavior t empty and K dm are illustrated in Figure 7. Generally, t empty decreases with increasing pressure drop, which indicates faster release behavior of mannitol powder. The presence of capsule significantly increased t empty as expected, as mannitol powder has to first exit the ends of the pierced holes from the capsule. Despite having non-converged fits for some capsule experiments, increase in t PO values, as shown in Table 3, reflects this prolonged nature of powder release due to the presence of capsule. The emptying behavior during the decay phase also showed interesting behavior. First, regardless of whether the mannitol was contained in capsule or not, an increase in K dm was observed with increasing pressure drop, especially at lower

8 TABLE 4 Dependency values and coefficient correlation for each estimated parameter for the initial release and single-decay rate models (n D 3; mean SD) Flow rate (L min 1 ) Initial release (sigmoidal) model Single-rate decay model (s) (s) (s 1 ) tempty t50 Kdm Bo %PO 0 R 2 Ao R 2 Without capsule With capsule LR LR LR HR HR HR LR LR60 a LR90 a HR HR60 b HR90 a a Experimental data could not be converged to Equation (1). b Only two sample experiments converged to Equation (1). 908

9 PARTICLE SIZE DISTRIBUTION AND POWDER RELEASE BEHAVIOR 909 FIG. 6. Initial obscuration profiles of individual experiments from the low-resistance RS01 Ò at 90 L min 1 (a) without, and (b) with a capsule. FIG. 7. Influence of pressure drop on the estimated rate constant parameters for (a) time constant, t empty, and (b) single-decay rate constant, K dm (n D 3; mean SD). FIG. 8. Scatter plots showing the effect of estimated parameters (a) t empty, and (b) K dm on X 50 from the low- and high-resistance RS01 Ò.

10 910 B. K. HUYNH ET AL. pressure drops. No significant differences in K dm were observed when comparing dispersion with and without a capsule at each tested flow rates; however K dm significantly decreased when mannitol was dispersed using the LR with capsule (0.30 kpa) at 30 L min 1. An alternative method for examining the relationship between the kinetics of powder release and the dispersion performance of mannitol powder is to create scatter plots of the data. Figure 8 displays the scatter plots partnering each estimated parameter with their corresponding volume medium diameter obtained from the data collected with the Spraytec. Figure 8a shows the relationship between t empty and X 50 values. The sample data concerning the dispersion of mannitol with a capsule displayed less variation in X 50 and a wider scattering of points over the entire range of t empty values when compared with experiments without a capsule. Regression analysis of both capsule-free and capsule experiments revealed the slope value to be significantly close to zero at 95% CI, indicating the dispersion performance of mannitol powder to be independent of initial emptying kinetics (p ). On the contrary, the slopes of both capsule-free and capsule experiments were significantly different from zero at the 95% CI level (p ), revealing an inverse relationship between K dm and X 50 (Figure 8b) This gives compelling evidence that the deagglomeration potential of mannitol powder is statistically dependent on the final powder release kinetics regardless of whether a capsule is present or not, as opposed to the initial release behavior. 4. DISCUSSION Many types of DPIs have been developed for delivering capsule-based products. These devices are reasonably cheap to manufacture, relatively simple in design, and effective in use. In this study, factors such as device resistance, sample flow rate, rates of powder emptying, and presence of a capsule were found to influence the degree of deagglomeration of mannitol powder, with some factors having a more pronounced effect than others do. It was found that not only the structural design (i.e. air inlet area) influences the device resistance to airflow and associated pressure drops but the presence of a capsule also influences these. It has been reported that the pressure drop across the device should be sufficient to generate enough turbulence within the device to deagglomerate powder formulation, and should provide a reproducible emitted dose across a wide range of airflow rates. Although many conflicting views still exist on the actual dispersion mechanism of dry powder formulations, such details are not the focus in this study. Instead, the purpose of this study is to emphasize how the supplied energy from the airflow translates into the aerosolization process of powder deagglomeration, i.e. how it influences the motion and physical state of capsule for capsule-based DPIs. It has been noted in this study that the shattering of capsule or significant enlargement in capsule-aperture size occurred for all experiments in the HR DPI at 90 L min 1, which could have potentially changed deagglomeration and emptying behavior. In addition, if fragments of the capsule exit the device, they will be inhaled by the patient and could cause irritation in their throats. Therefore, ensuring proper metering and free-flowing properties of powder from the capsule ends as well as maintaining the structural integrity of capsule can potentially warrant better control and less variability in the emitted dose and particle size distribution of the dose discharged from capsule-based DPI. Hence, this study demonstrates the need to consider the physical influences of capsule on both release behavior and deagglomeration performance of capsule-based DPIs. 5. CONCLUSIONS As powder dispersion from DPI systems is a timedependent process, the results presented in this study, obtained by laser diffraction, indicate that mannitol powder released from an inhaler with the presence of capsule behaves differently than the inhaler without capsule. The shape and intensity of obscuration profiles can give critical insight into the release of powder, which has not been achieved with conventional impaction methods. A modeling technique to quantitatively compare powder release behavior was presented and applied to the study of the influence of capsule on the aerosolization performance and release behavior of micronized mannitol powder from two different capsule-based DPIs. REFERENCES Behara, S. R., Farkas, D. R., Hindle, M., and Longest, P. W. (2014). Development of a High Efficiency Dry Powder Inhaler: Effects of Capsule Chamber Design and Inhaler Surface Modifications. Pharm. Res., 31(2): Behara, S. R. B., Kippax, P., Larson, I., Morton, D. A. V., and Stewart, P. (2011). Kinetics of Emitted Mass A Study with Three Dry Powder Inhaler Devices. Chem. Eng. Sci., 66(21): Behara, S. R. B., Larson, I., Kippax, P., Stewart, P., and Morton, D. A. V. (2012). Insight into Pressure Drop Dependent Efficiencies of Dry Powder Inhalers. Eur. J. Pharm. Sci., 46(3): Cegla, U. H. (2004). Pressure and Inspiratory Flow Characteristics of Dry Powder Inhalers. Respir. Med., 98(Supplement 1(0)):S22 S28. Chew, N. Y., and Chan, H. K. (1999). Influence of Particle Size, Air Flow, and Inhaler Device on the Dispersion of Mannitol Powders as Aerosols. Pharm. Res., 16(7): Chew, N. Y., Chan, H. K., Bagster, D. F., and Mukhraiyab, J. (2002). Characterization of Pharmaceutical Powder Inhalers: Estimation of Energy Input for Powder Dispersion and Effect of Capsule Device Configuration. J. Aerosol Sci., 33: Clark, A. R., and Hollingworth, A. M. (1993). The Relationship Between Powder Inhaler Resistance and Peak Inspiratory Conditions in Healthy Volunteers Implications for in vitro Testing. J. Aerosol. Med., 6(2): Coates, M. S., Chan, H. K., Fletcher, D. F., and Raper, J. A. (2005a). Influence of Air Flow on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses. Pharm. Res., 22(9):

11 PARTICLE SIZE DISTRIBUTION AND POWDER RELEASE BEHAVIOR 911 Coates, M. S., Chan, H. K., Fletcher, D. F., and Raper, J. A. (2006). Effect of Design on the Performance of a Dry Powder Inhaler Using Computational Fluid Dynamics. Part 2: Air Inlet Size. J. Pharm. Sci., 95(6): Coates, M. S., Fletcher, D. F., Chan, H. K., and Raper, J. A. (2005b). The Role of Capsule on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses. Pharm. Res., 22(6): de Boer, A. H., Gjaltema, D., Hagedoorn, P., Schaller, M., Witt, W., and Frijlink, H. W. (2002). Design and Application of a New Modular Adapter for Laser Diffraction Characterization of Inhalation Aerosols. Int. J. Pharm., 249(1 2): Elkins, M. R., Anderson, A. D., Perry, C. P., Daviskas, E., and Charlton, B. (2014). Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device. Open Respir. Med. J., 8:8 13. Hindle, M., and Byron, P. R. (1995). Dose Emissions from Marketed Dry Powder Inhalers. Int. J. Pharm., 116(2): Hira, D., Okuda, T., Ichihashi, M., Mizutani, A., Ishizeki, K., Okada, T., et al. (2012). Influence of Peak Inspiratory Flow Rates and Pressure Drops on Inhalation Performance of Dry Powder Inhalers. Chem. Pharm. Bull. (Tokyo), 60(3): Islam, N., and Cleary, M. J. (2012). Developing an Efficient and Reliable Dry Powder Inhaler for Pulmonary Drug Delivery A Review for Multidisciplinary Researchers. Med. Eng. Phys., 34(4): Jiang, L., Tang, Y., Zhang, H., Lu, X., Chen, X., and Zhu, J. (2012). Importance of Powder Residence Time for the Aerosol Delivery Performance of a Commercial Dry Powder Inhaler Aerolizer((R)). J. Aerosol. Med. Pulm. Drug Deliv., 25(5): Kippax, P., and Morton, D. A. (2008). Unlocking the Secrets of the Dry Powder Inhaler Plume. Drug Deliv. Tech., 8(1): Knott, G., and Shrager, R. (1972). On-Line Modeling by Curve-Fitting. SIG- GRAPH Comput. Graph. 6(4): Sim, S., Margo, K., Parks, J., Howell, R., Hebbink, G. A., Orlando, L., et al. (2014). An Insight Into Powder Entrainment and Drug Delivery Mechanisms from a Modified Rotahaler. Int. J. Pharm., 477(1 2): Suarez, S., and Hickey, A. J. (2000). Drug Properties Affecting Aerosol Behavior. Respir. Care, 45(6): Zhu, B., Young, P. M., Ong, H. X., Crapper, J., Flodin, C., Qiao, E. L., et al (2015). Tuning Aerosol Performance using the Multibreath Orbital(R) Dry Powder Inhaler Device: Controlling Delivery Parameters and Aerosol Performance via Modification of Puck Orifice Geometry. J. Pharm. Sci., 104(7):

COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES

COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation

More information

CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES

CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing

More information

University of Groningen. Technology in practice Lexmond, Anne

University of Groningen. Technology in practice Lexmond, Anne University of Groningen Technology in practice Lexmond, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document

More information

Understanding cascade impaction and its importance for inhaler testing

Understanding cascade impaction and its importance for inhaler testing Understanding cascade impaction and its importance for inhaler testing Mark Copley, Technical Sales Manager Inhalation product development is an important area of activity for the pharmaceutical sector.

More information

The Use of Physics-Based Modeling to Better Design Drug- Device Interface. Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ

The Use of Physics-Based Modeling to Better Design Drug- Device Interface. Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ The Use of Physics-Based Modeling to Better Design Drug- Device Interface Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ Presentation Outline Physics-based modeling in pharmaceutical industry Pulmonary

More information

Effects of viscosity, pump mechanism and nozzle geometry on nasal spray droplet size

Effects of viscosity, pump mechanism and nozzle geometry on nasal spray droplet size ILASS Europe 21, 23rd Annual Conference on Liquid Atomization and Spray Systems, Brno, Czech Republic, September 21 P. Kippax 1, J. Suman 2, A. Virden 1* and G. Williams 3 1 Malvern Instruments, Grovewood

More information

OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER

OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references

More information

Effect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers

Effect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers Effect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers Received March 3, 2000; Accepted April 5, 2000, Published April 20, 2000 Varsha Chavan

More information

Testing inhalers. One of the longstanding challenges facing the

Testing inhalers. One of the longstanding challenges facing the Testing inhalers This article investigates how the industry can test inhalers in a way that is most representative of typical use. One of the longstanding challenges facing the United States Pharmacopeia

More information

Pulmonary deposition of inhaled drugs

Pulmonary deposition of inhaled drugs Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the last 5 years

More information

DRY POWDER INHALER; SPECIAL EMPHASIS TO FORMULATION, DEVICES, CHARACTERIZATION & PROCESS VALIDATION PROTOCOL: A REVIEW

DRY POWDER INHALER; SPECIAL EMPHASIS TO FORMULATION, DEVICES, CHARACTERIZATION & PROCESS VALIDATION PROTOCOL: A REVIEW Available online on 15.05.2017 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open access to Pharmaceutical and Medical research 2011-17, publisher and licensee JDDT, This is an Open

More information

Novel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations.

Novel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations. 1 Novel Application of an Old Excipient L-Leucine- Improving Physical and Aerosolization Stability of Spray Dried Amorphous DPI Formulations. Nivedita Shetty 1, Dmitry Zemlyanov 2, Qi (Tony) Zhou 1 1 Department

More information

The Kinetics of De-agglomeration of Magnesium Stearate Dry-Coated Salbutamol Sulphate Powders

The Kinetics of De-agglomeration of Magnesium Stearate Dry-Coated Salbutamol Sulphate Powders KONA Powder and Particle Journal No. 32 (2015) 131 142/Doi:10.14356/kona.2015001 Original Research Paper The Kinetics of De-agglomeration of Magnesium Stearate Dry-Coated Salbutamol Sulphate Powders Jiani

More information

INTRODUCTION. size and total nozzle area decrease with stage number. Volumetric air flow rate through

INTRODUCTION. size and total nozzle area decrease with stage number. Volumetric air flow rate through CASCADE I M P A C T I O N Optimizing Cascade Impactor Testing for Characterizing Orally Inhaled & Nasal Drug Products By: Mark Copley INTRODUCTION Cascade impaction is a core analytical technique for characterizing

More information

Citation for published version (APA): Westerman, E. M. (2009). Studies on antibiotic aerosols for inhalation in cystic fibrosis s.n.

Citation for published version (APA): Westerman, E. M. (2009). Studies on antibiotic aerosols for inhalation in cystic fibrosis s.n. University of Groningen Studies on antibiotic aerosols for inhalation in cystic fibrosis Westerman, Elisabeth Mechteld IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)

More information

Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi)

Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi) Respiratory Drug Delivery Europe 2017 Nagel and Suggett Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi) Mark W. Nagel and Jason A. Suggett

More information

Understanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016

Understanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016 Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,

More information

Current Challenges and Opportunities in Demonstrating Bioequivalence

Current Challenges and Opportunities in Demonstrating Bioequivalence Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled

More information

University of Groningen. Optimisation of dry powder inhalation Boer, Anne Haaije de

University of Groningen. Optimisation of dry powder inhalation Boer, Anne Haaije de University of Groningen Optimisation of dry powder inhalation Boer, Anne Haaije de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

Assessing the role of breathing simulators in OIP testing

Assessing the role of breathing simulators in OIP testing As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can

More information

DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs

DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs Issue: March 2016, Posted Date: 3/1/2016 DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs INTRODUCTION In the development of orally inhaled and nasal products

More information

CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA. Steve Newman, PhD Nottingham, UK November 2006

CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA. Steve Newman, PhD Nottingham, UK November 2006 IPAC-RS Conference 6-8 November 2006 CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA Steve Newman, PhD Nottingham, UK November 2006 IPAC-RS Conference 6-8 November 2006 1 EFFECT OF PARTICLE SIZE ON

More information

A Comparison of Aerosol Performance Using Standardized Entrainment Tubes vs. Dry Powder Inhaler Devices

A Comparison of Aerosol Performance Using Standardized Entrainment Tubes vs. Dry Powder Inhaler Devices A Comparison of Aerosol Performance Using Standardized Entrainment Tubes vs. Dry Powder Inhaler Devices Zhen Xu 1 and Anthony J Hickey 2 1 Division of Molecular Pharmaceutics, Eshelman School of Pharmacy,

More information

Go With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific

Go With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.

More information

Research Article. *Corresponding author Mahesh M.Giri

Research Article. *Corresponding author Mahesh M.Giri Scholars Academic Journal of Pharmacy (SAJP) ISSN 2320-4206 Sch. Acad. J. Pharm., 2013; 2(3):260-267 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)

More information

21/03/2011 AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY. Fundamentals of aerosols

21/03/2011 AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY. Fundamentals of aerosols AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY Steve Newman Scientific Consultant Norfolk, UK steve.newman@physics.org

More information

RDD Europe 2009 Workshop

RDD Europe 2009 Workshop RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution. An Introduction to Differentiating

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS European Medicines Agency Inspections London, 16 February 2005 Doc Ref.: EMEA/CHMP/QWP/49313/2005 corr. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF

More information

Device Design Similarity

Device Design Similarity Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity

More information

Dry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success

Dry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success 3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has

More information

EXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION

EXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION EXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION The inhalation route is a fast and effective way of delivering medication, both locally to the

More information

Development of a Dry Powder Multi-dose Inhaler using Computational Modeling

Development of a Dry Powder Multi-dose Inhaler using Computational Modeling ENGINEER - Vol. XXXXII, No. 03, pp. [57-65], 2009 The Institution of Engineers, Sri Lanka Development of a Dry Powder Multi-dose Inhaler using Computational Modeling M.A.D.A.Sudeera, V.P.C.Dassanayake,

More information

IPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.

IPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M. IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different

More information

Metered Dose Inhaler Technology

Metered Dose Inhaler Technology Metered Dose Inhaler Technology Edited by Tol S. Purewal and David J. W. Grant Interpharm Press, Inc. Buffalo Grove, Illinois Contents 1. INTRODUCTION 1 T. S. Purewal Definition of the Metered Dose Inhaler

More information

A New Shadowgraphic Imaging Method for the Suspension Stability Analysis of Pressurized Metered Dose Inhalers

A New Shadowgraphic Imaging Method for the Suspension Stability Analysis of Pressurized Metered Dose Inhalers Respiratory Drug Delivery 2018 Wang et al. A New Shadowgraphic Imaging Method for the Suspension Stability Analysis of Pressurized Metered Dose Inhalers Hui Wang, 1 Penny Tan, 2 David Barona, 1 Grace Li,

More information

Process Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations

Process Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process

More information

Achieving Optimal Particle Size Distribution in Inhalation Therapy

Achieving Optimal Particle Size Distribution in Inhalation Therapy Achieving Optimal Particle Size Distribution in Inhalation Therapy By Bob Bruno Inhalation therapy has proven to be an effective method of administering a number of pharmaceuticals for more than a century.

More information

Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016

Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016 Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies Julie D. Suman, Ph.D. March 29, 2016 AGENDA Regulatory Approaches for Bioequivalence (BE) Compendial Testing Vs Pharmaceutical Equivalence

More information

PREMIXES FOR MEDICATED FEEDING STUFFS FOR VETERINARY USE. Praeadmixta ad alimenta medicata ad usum veterinarium. Effervescent powders

PREMIXES FOR MEDICATED FEEDING STUFFS FOR VETERINARY USE. Praeadmixta ad alimenta medicata ad usum veterinarium. Effervescent powders Preparations for inhalation administered in or with water or another suitable liquid. They may also be swallowed directly. They are presented as single-dose or multidose preparations. Where applicable,

More information

Drug/Device Combination Products: Bioequivalence

Drug/Device Combination Products: Bioequivalence Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence

More information

TEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.

TEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006. (19) TEPZZ _784 A_T (11) EP 3 17 842 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 07.06.17 Bulletin 17/23 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/439 (06.01) (21) Application number: 1197874.9

More information

EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010

EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010 1 EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010 Overview 2 EPAG, what is it?, background, this project Regulatory

More information

Patient. Device Clinician. Safety & efficacy

Patient. Device Clinician. Safety & efficacy Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331

More information

INTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS

INTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS INTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS Here, Filipa Maia, PhD, and Maria Palha, MSc, both Scientists at Hovione, report a study whose objective was to establish relationships between

More information

Respiratory. Martin Jetzer DDL27 Edinburgh December 2016

Respiratory. Martin Jetzer DDL27 Edinburgh December 2016 Respiratory Investigating the Effect of the Force Control Agent Magnesium Stearate in Fluticasone Propionate Dry Powder Inhaled Formulations with Single Particle Aerosol Mass Spectrometry Martin Jetzer

More information

Case Study 1: Pharmaceutical Development of EXUBERA

Case Study 1: Pharmaceutical Development of EXUBERA Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human

More information

FRI aerosol. deposition. A unique way to look at regional inhaled drug deposition.

FRI aerosol. deposition. A unique way to look at regional inhaled drug deposition. FRI aerosol deposition A unique way to look at regional inhaled drug deposition www.fluidda.com EXECUTIVE SUMMARY FRI - AN UPDATE OF SCINTIGRAPHY FRI deposition technology is based on CT imaging, and uses

More information

Delay Between Actuation and Shaking of a Hydrofluoroalkane Fluticasone Pressurized Metered-Dose Inhaler

Delay Between Actuation and Shaking of a Hydrofluoroalkane Fluticasone Pressurized Metered-Dose Inhaler Delay Between Actuation and Shaking of a Hydrofluoroalkane Fluticasone Pressurized Metered-Dose Inhaler Ariel Berlinski MD, Dirk von Hollen, John N Pritchard PhD, and Ross HM Hatley PhD BACKGROUND: Inhaled

More information

Real time measurement of aerosol size distribution using MASTERSIZER

Real time measurement of aerosol size distribution using MASTERSIZER Indian Journal of Pure & Applied Physics Vol. 44, August 2006, pp. 576-580 Real time measurement of aerosol size distribution using MASTERSIZER R Baskaran*, V Subramanian & T S Selvakumaran Radiological

More information

Misty Max 10 nebulizer

Misty Max 10 nebulizer AirLife brand Misty Max 10 nebulizer Purpose Introduction Delivery of nebulized medication to the lungs is a complex process dependant upon a variety of clinical and device-related variables. Patient breathing

More information

NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS

NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of

More information

2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus

2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus 2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus Patient Perspective Alpha-1 1 Foundation John W. Walsh Patient Focus Personal perspective Challenges and lessons Importance

More information

REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION

REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION In this article, Heli Chauhan, Senior Applications Chemist, and Linda (Lingzhi) Liao, Field Applications Scientist, both of Proveris

More information

Teerapol SRICHANA,*,a Anthony BRAIN, b Christopher MARRIOTT, c and Gary Peter MARTIN c

Teerapol SRICHANA,*,a Anthony BRAIN, b Christopher MARRIOTT, c and Gary Peter MARTIN c February 2000 Chem. Pharm. Bull. 48(2) 167 174 (2000) 167 A Study of Drug Carrier Interactions in Dry Powder Inhaler Formulations Using the Andersen Cascade Impactor, X-Ray Microanalysis and Time of Flight

More information

FRI aerosol. deposition. A unique way to look at regional inhaled drug deposition.

FRI aerosol. deposition. A unique way to look at regional inhaled drug deposition. FRI aerosol deposition A unique way to look at regional inhaled drug deposition www.fluidda.com EXECUTIVE SUMMARY Since 2005, Functional Respiratory Imaging (FRI) has been used many times to evaluate the

More information

Redefining Continuous Aerosol Drug Delivery 2015 PM223

Redefining Continuous Aerosol Drug Delivery 2015 PM223 Redefining Continuous Aerosol Drug Delivery 2015 PM223 Explanation of Continuous via Traditional Small Volume (Jet) Nebulizer Traditional small volume (jet) nebulizers require compressed gas to aerosolize

More information

COPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?

COPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD? Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes

More information

Research Article. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products

Research Article. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products The AAPS Journal, Vol. 17, No. 6, November 2015 ( # 2015) DOI: 10.1208/s12248-015-9802-0 Research Article De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in

More information

University of Groningen. Optimisation of dry powder inhalation de Boer, Anne

University of Groningen. Optimisation of dry powder inhalation de Boer, Anne University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check

More information

Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing

Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing INSTRUMENTATION» Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing Mark Copley Director Copley Scientific The recent introduction

More information

PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP (EPAG)

PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP (EPAG) PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP () J.P. Mitchell on behalf of members of the European Pharmaceutical Aerosol

More information

Block-upscaling of transport in heterogeneous aquifers

Block-upscaling of transport in heterogeneous aquifers 158 Calibration and Reliability in Groundwater Modelling: From Uncertainty to Decision Making (Proceedings of ModelCARE 2005, The Hague, The Netherlands, June 2005). IAHS Publ. 304, 2006. Block-upscaling

More information

Caption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).

Caption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31). Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products

More information

Formulation Considerations for Inhaled Products

Formulation Considerations for Inhaled Products Formulation Considerations for Inhaled Products Formulation Considerations of Inhaled Products Inhalation Therapy Nebulizers and Formulations Dry Powder Inhalers and Formulations Metered Dose Inhalers

More information

Redefining Continuous Aerosol Drug Delivery PM223

Redefining Continuous Aerosol Drug Delivery PM223 Redefining Continuous Aerosol Drug Delivery PM223 Explanation of Continuous via Traditional Small Volume (Jet) Nebulizer Traditional small volume (jet) nebulizers require compressed gas to aerosolize medication

More information

Moving to More Realistic In Vitro Testing of OIDPs

Moving to More Realistic In Vitro Testing of OIDPs Moving to More Realistic In Vitro Testing of OIDPs IPAC-RS/UF 2014 Conference: Orlando Inhalation Conference - Approaches in International Regulation Renishkumar Delvadia, PhD. Food and Drug Administration

More information

Predictive modeling of deposition, dissolution, absorption and systemic exposure

Predictive modeling of deposition, dissolution, absorption and systemic exposure Predictive modeling of deposition, dissolution, absorption and systemic exposure IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Per Bäckman and Bo Olsson, AstraZeneca R&D, Mölndal Sweden The views

More information

IVIVC in Pediatric OIPs

IVIVC in Pediatric OIPs IPAC-RS/UF Orlando Conference 2014 March 20, 2014 IVIVC in Pediatric OIPs Herbert Wachtel Declaration of Conflicts of Interest H. Wachtel is employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.

More information

AEROSOL THERAPY: THE PRACTICALITIES

AEROSOL THERAPY: THE PRACTICALITIES AEROSOL THERAPY: THE PRACTICALITIES Lester I. Harrison, PhD Section Head, Clinical Pharmacokinetics, 3M Pharmaceuticals, 3M Center 270-3S-05, St. Paul, MN, USA 55144 liharrison@mmm.com Introduction: Horses,

More information

Lessons Learned from Approval of Generic Nasal Products

Lessons Learned from Approval of Generic Nasal Products Lessons Learned from Approval of Generic Nasal Products Julie D. Suman, Ph.D President, Next Breath IPAC-RS/UF Orlando Inhalation Conference: Approaches in International Regulation March 20, 2014 Objectives

More information

Investigations into Domestic Household Aerosols Air Freshener and body spray

Investigations into Domestic Household Aerosols Air Freshener and body spray ILASS Europe 2010, 23rd Annual Conference on Liquid Atomization and Spray Systems, Brno, Czech Republic, September 2010 Investigations into Domestic Household Aerosols Air Freshener and body spray R.A.

More information

What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation

What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects Jolyon P. Mitchell, Ph.D. Trudell Medical International London, Canada IPAC-RS Conference November 2006 1 Context of Presentation This talk

More information

Computational Fluid Dynamics Modeling of Amsino OneMask Oxygen Mask

Computational Fluid Dynamics Modeling of Amsino OneMask Oxygen Mask Computational Fluid Dynamics Modeling of Amsino OneMask Oxygen Mask Abstract This study s objective was to model the Amsino OneMask Oxygen Mask using Computational Fluid Dynamics (CFD). A three-dimensional

More information

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical www.cirruspharm.com February 2014 INTRODUCTION Cirrus, a Kemwell company, is frequently

More information

The pulmonary route is gaining increasing

The pulmonary route is gaining increasing ELECTRONICALLY REPRINTED FROM FEBRUARY 2014 Pulmonary Drug Delivery Particle Engineering for Inhaled Therapeutics Moderated by Adeline Siew, PhD Industry experts discuss the various factors affecting drug

More information

Inhalation Product Research at FDA

Inhalation Product Research at FDA Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views

More information

Assessing Quality of Inhaled Products And Links to Efficacy and Safety

Assessing Quality of Inhaled Products And Links to Efficacy and Safety Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation

More information

HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION

HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION 2 3 QUALICAPS HISTORY Over one hundred years of experience in the manufacturing and filling of hard two-piece capsules Qualicaps

More information

IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING

IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING In this piece, Mark Copley, Sales Director of Copley Scientific, provides some background on mouth-throat models for

More information

Everything for Inhalation

Everything for Inhalation Everything for Inhalation Everything for Inhalation Inhalation drug product development at Hovione has a strong focus on formulation for Dry Powder Inhalers (DPI), particularly for capsule-based and reservoir-based

More information

EPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing. Overview of AIM EDA

EPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing. Overview of AIM EDA EPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing Overview of AIM EDA Jolyon Mitchell 1 and Mark Copley 2 1 Trudell Medical

More information

Physical and chemical properties of cigarette, heated tobacco and e-cigarette aerosols

Physical and chemical properties of cigarette, heated tobacco and e-cigarette aerosols SPS3 N2ff Physical and chemical properties of cigarette, heated tobacco and e-cigarette aerosols Caner U Yurteri, Jennifer Margham, Kevin McAdam, Mark Forster, Chuan Liu, Chris Wright, Derek Mariner, Chris

More information

Noninvasive Blood Glucose Analysis using Near Infrared Absorption Spectroscopy. Abstract

Noninvasive Blood Glucose Analysis using Near Infrared Absorption Spectroscopy. Abstract Progress Report No. 2-3, March 31, 1999 The Home Automation and Healthcare Consortium Noninvasive Blood Glucose Analysis using Near Infrared Absorption Spectroscopy Prof. Kamal Youcef-Toumi Principal Investigator

More information

Controlled Particle Dispersion : Applying Vortical Flow to Optimize Nasal Drug Deposition By: Marc Giroux, Peter Hwang, MD; and Ajay Prasad, PhD

Controlled Particle Dispersion : Applying Vortical Flow to Optimize Nasal Drug Deposition By: Marc Giroux, Peter Hwang, MD; and Ajay Prasad, PhD Controlled Particle Dispersion : Applying Vortical Flow to Optimize Nasal Drug Deposition By: Marc Giroux, Peter Hwang, MD; and Ajay Prasad, PhD Nasal delivery of local and systemic medical therapies is

More information

Inhalers and nebulizers: basic principles and preliminary measurements

Inhalers and nebulizers: basic principles and preliminary measurements Inhalers and nebulizers: basic principles and preliminary measurements Ondrej Misik 1*, Frantisek Lizal 1, Vahid Farhikhteh Asl 2, Miloslav Belka 1, Jan Jedelsky 1, Jakub Elcner 1 and Miroslav Jicha 1

More information

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Poonam Sheth, PharmD, PhD, Research Scientist, Inhalation Matthew T. Marmura, Research Scientist, Inhalation Recipharm is frequently asked to help

More information

Year in review. Vit Perlik Director of Regulatory Science and Clinical Development

Year in review. Vit Perlik Director of Regulatory Science and Clinical Development Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration

More information

Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics

Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics Ariel Berlinski MD and David Pennington BACKGROUND: Albuterol hydrofluoroalkane

More information

What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG

What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG VM The authors describe the problems that arise with metered-dose and dry-powder inhalers,

More information

The influence of lactose particle size on dry powder inhalation performance

The influence of lactose particle size on dry powder inhalation performance The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are

More information

RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms

RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms Asian Journal of Chemistry Vol. 22, No. 7 (2010), 5067-5071 RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms A. LAKSHMANA RAO*, G. TARAKA RAMESH and J.V.L.N.S. RAO Department of Pharmaceutical

More information

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy Starch 1500 Application Data Partially Pregelatinized Maize Starch Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy OBJECTIVE To characterize

More information

Delivery of Iloprost Inhalation Solution With the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery Systems: An In Vitro Study

Delivery of Iloprost Inhalation Solution With the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery Systems: An In Vitro Study Delivery of Iloprost Inhalation Solution With the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery Systems: An In Vitro Study Robert E Van Dyke MSc and Kurt Nikander BACKGROUND: Iloprost (Ventavis)

More information

University of Groningen. Optimisation of dry powder inhalation de Boer, Anne

University of Groningen. Optimisation of dry powder inhalation de Boer, Anne University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check

More information

Advanced Drug Delivery Reviews

Advanced Drug Delivery Reviews ADR-12134; No of Pages 16 Advanced Drug Delivery Reviews xxx (2011) xxx xxx Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr In silico

More information

Volume 2 (6), 2014, Page CODEN (USA)-IJPRUR, e-issn: International Journal of Pharma Research and Health Sciences

Volume 2 (6), 2014, Page CODEN (USA)-IJPRUR, e-issn: International Journal of Pharma Research and Health Sciences CODEN (USA)-IJPRUR, e-issn: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Simultaneous Determination of Salbutamol

More information

Device Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015

Device Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Device Change Management for Inhaled Products Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Topics to be covered Update on ISO/TC 084/WG 15: Guidelines for development of drug products- Quality

More information

Available online Research Article

Available online   Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(3):289-294 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Simultaneous UV-spectrophotometric estimation of

More information

Respiratory Therapy. Medical/Scientific/General Background

Respiratory Therapy. Medical/Scientific/General Background Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM

More information